FDA Approves Risankizumab (Skyrizi) for Pediatric Plaque Psoriasis and Psoriatic Arthritis Dr. Kamal Kant Kohli30 Jun 2026 8:30 PM ISTThe U.S. Food and Drug Administration has expanded the approved indications for Skyrizi to include the treatment of pediatric patients aged 6 years...
New study hints at the cause of a painful skin condition-and at a long-awaited potential treatment Dr. Kamal Kant Kohli26 Jun 2026 8:30 PM ISTImagine a skin condition so painful, people with it are reduced to crawling around their homes to avoid having to walk on thick and painful calluses....
Can diabetes and obesity drugs also help the skin? Dr. Kamal Kant Kohli23 Jun 2026 9:15 PM ISTGLP-1 receptor agonists are currently among the most widely discussed classes of drugs worldwide. They have gained popularity for their effectiveness...
Low-Dose Tirzepatide Improves Metabolic Health in Psoriasis and Obesity, suggests study Jacinthlyn Sylvia18 Jun 2026 10:15 PM ISTA new study published in the journal of Dermatology and Therapy showed that treatment with low-dose tirzepatide was linked to clinically significant...
Combined Tirzepatide and Ixekizumab Therapy Shows Dual Benefits in Psoriasis: JAMA Medha Baranwal17 May 2026 9:15 PM ISTUSA: A clinical trial has found that combining tirzepatide with ixekizumab led to significant improvements in skin clearance and weight reduction in...
GLP-1 Receptor Agonists Useful Adjunct in Psoriasis Management, Suggests Study Medha Baranwal5 May 2026 9:30 AM ISTUSA: Emerging evidence indicates that GLP-1 receptor agonists may play a supportive role alongside standard psoriasis therapies. Several studies have...
Biologics in Psoriasis Linked to Lower Risk of Ocular Surface Diseases: Study Jacinthlyn Sylvia23 April 2026 7:30 AM ISTA new study published in the recent issue of Eye journal revealed that among patients with psoriasis, use of biologic drugs (advanced...
SGLT2 Inhibitors Do Not Reduce Psoriasis Risk in T2DM: Study Dr Riya Dave17 April 2026 8:00 PM ISTSodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy fails to lower the risk of new-onset psoriasis among patients with type 2 diabetes mellitus...
Sun Pharma to Present ILUMYA, LEQSELVI, WINLEVI Data at AAD 2026, Showcases Dermatology Advances Parthika Patel29 March 2026 11:30 AM ISTNew Delhi: Sun Pharmaceutical Industries Limited has announced that it will present 14 scientific abstracts highlighting advances in alopecia areata,...
From Psoriasis to Psoriatic Arthritis: Strategies for Early Risk Modification Dr. Bhumika Maikhuri9 March 2026 11:15 AM ISTKey Summary The transition from psoriasis to psoriatic arthritis (PsA) is driven by several modifiable risk factors, including obesity, severe...
Biologic Therapy safe in Psoriasis Patients With Active or Recent Malignancy, suggests research Jacinthlyn Sylvia1 March 2026 8:45 PM ISTA new study published in the Journal of American Academy of Dermatology showed that biologic therapies were linked to cancer progression, recurrence,...
